Evidence map›Paper›PMID 36340694›Full record

ArticleFrontiers in molecular neuroscience2022

Development of ASIC1a ligand-gated ion channel drug screening assays across multiple automated patch clamp platforms.

John Ridley, Sam Manyweathers, Raymond Tang, Tom Goetze, Nadine Becker, Ilka Rinke-Weiß, Robert Kirby, Alison Obergrussberger, Marc Rogers

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

John RidleyMetrion Biosciences Ltd., Cambridge, United Kingdom.
Sam ManyweathersMetrion Biosciences Ltd., Cambridge, United Kingdom.
Raymond TangMetrion Biosciences Ltd., Cambridge, United Kingdom.
Tom GoetzeNanion Technologies GmbH, Munich, Germany.
Nadine BeckerNanion Technologies GmbH, Munich, Germany.
Ilka Rinke-WeißNanion Technologies GmbH, Munich, Germany.
Robert KirbyMetrion Biosciences Ltd., Cambridge, United Kingdom.
Alison ObergrussbergerNanion Technologies GmbH, Munich, Germany.
Marc RogersMetrion Biosciences Ltd., Cambridge, United Kingdom.
Nanion (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human acid-sensing ion channels (ASIC) are ligand-gated ionotropic receptors expressed widely in peripheral tissues as well as sensory and central neurons and implicated in detection of inflammation, tissue injury, and hypoxia-induced acidosis. This makes ASIC channels promising targets for drug discovery in oncology, pain and ischemia, and several modulators have progressed into clinical trials. We describe the use of hASIC1a as a case study for the development and validation of low, medium and high throughput automated patch clamp (APC) assays suitable for the screening and mechanistic profiling of new ligands for this important class of ligand-gated ion channel. Initial efforts to expand on previous manual patch work describing an endogenous hASIC1a response in HEK cells were thwarted by low current expression and unusual pharmacology, so subsequent work utilized stable hASIC1a CHO cell lines. Ligand-gated application protocols and screening assays on the Patchliner, QPatch 48, and SyncroPatch 384 were optimized and validated based on pH activation and nM-μM potency of reference antagonists (e.g., Amiloride, Benzamil, Memantine, Mambalgin-3, A-317567, PcTx1). By optimizing single and stacked pipette tip applications available on each APC platform, stable pH-evoked currents during multiple ligand applications enabled cumulative EC

Indexed as

acid-sensitive ion channelautomated patch clampdrug discoveryligand-gated ionotropic receptorscreening assay

Identifiers

PMID36340694
PMCPMC9629855
OpenAlexW4306849468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.